We must optimize stent deployment & maintain a registry of how well (or poorly) we use drug-eluting stents. Instead of asking “Which stent?” or “How much anti-platelet therapy?” we must ask “How effectively are we deploying our stents?”
FDA says drug-eluting stents are safe & effective in stable patients with single-vessel disease; even so, they'll have to take Plavix (clopidogrel) & aspirin for a year or more...up to a lifetime. High-risk patients with multivessel disease are much more
Human resolvin E1 inhibits both the migration of inflammatory cells to sites of inflammation and the turning on of other inflammatory cells. Aspirin-triggered resolivins are made from omega-3 fatty acids by cellular enzymes. COX-2 inhibitors also inhibit
Editorial on the "Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial," which studied optimal medical treatment with or without percutaneous coronary intervention (PCI) for stable coronary disease.